DK3456712T3 - Hidtil ukendte 2,4,6-trisubstitueret S-triazinforbindelse, fremgangsmåde til fremstilling deraf og anvendelse deraf - Google Patents
Hidtil ukendte 2,4,6-trisubstitueret S-triazinforbindelse, fremgangsmåde til fremstilling deraf og anvendelse deraf Download PDFInfo
- Publication number
- DK3456712T3 DK3456712T3 DK17795572.1T DK17795572T DK3456712T3 DK 3456712 T3 DK3456712 T3 DK 3456712T3 DK 17795572 T DK17795572 T DK 17795572T DK 3456712 T3 DK3456712 T3 DK 3456712T3
- Authority
- DK
- Denmark
- Prior art keywords
- trisubstituted
- novel
- preparation
- triazine compound
- triazine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
- C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610325809 | 2016-05-12 | ||
| PCT/CN2017/083914 WO2017193954A1 (zh) | 2016-05-12 | 2017-05-11 | 新型2,4,6-三取代均三嗪化合物及其制备方法和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3456712T3 true DK3456712T3 (da) | 2022-05-30 |
Family
ID=60266897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17795572.1T DK3456712T3 (da) | 2016-05-12 | 2017-05-11 | Hidtil ukendte 2,4,6-trisubstitueret S-triazinforbindelse, fremgangsmåde til fremstilling deraf og anvendelse deraf |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10611736B2 (da) |
| EP (1) | EP3456712B1 (da) |
| JP (1) | JP6987125B2 (da) |
| KR (1) | KR102379959B1 (da) |
| CN (1) | CN109311825B (da) |
| AU (1) | AU2017262920B2 (da) |
| BR (1) | BR112018072869B1 (da) |
| CA (1) | CA3023854A1 (da) |
| DK (1) | DK3456712T3 (da) |
| ES (1) | ES2913982T3 (da) |
| RU (1) | RU2737085C2 (da) |
| SG (1) | SG11201809760TA (da) |
| WO (1) | WO2017193954A1 (da) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3023854A1 (en) * | 2016-05-12 | 2017-11-16 | Nanjing Shiqi Pharmaceutical Co. Ltd. | Novel 2,4,6-trisubstituted s-triazine compounds, preparation method therefor, and use thereof |
| CN109796407A (zh) * | 2018-12-29 | 2019-05-24 | 鼎元(天津)生物医药科技有限公司 | 一种模块化制备化学小分子探针的方法及应用 |
| WO2022166748A1 (zh) * | 2021-02-03 | 2022-08-11 | 滁州市洛达生物科技有限公司 | 治疗或预防波形蛋白介导的疾病的化合物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100107509A (ko) * | 2001-09-14 | 2010-10-05 | 9222-9129 퀘벡 인코포레이티드 | 히스톤 데아세틸라아제의 억제제 |
| EP1882475A1 (en) * | 2006-07-26 | 2008-01-30 | Novartis AG | Method of treating disorders mediated by the fibroblast growth factor receptor |
| WO2008127719A1 (en) * | 2007-04-13 | 2008-10-23 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to kinase inhibitors |
| US20110112193A1 (en) * | 2008-05-14 | 2011-05-12 | Peter Nilsson | Bis-aryl compounds for use as medicaments |
| CN104230831B (zh) * | 2008-05-23 | 2016-08-24 | 惠氏有限责任公司 | 作为PI3激酶和mTOR抑制剂的三嗪化合物 |
| CN102573482A (zh) * | 2009-06-09 | 2012-07-11 | 加利福尼亚资本权益有限责任公司 | 苯乙烯基-三嗪衍生物及其治疗应用 |
| EP2440056A4 (en) * | 2009-06-09 | 2012-12-05 | California Capital Equity Llc | DERIVATIVES OF UREIDOPHENYL SUBSTITUTED TRIAZINE AND THERAPEUTIC APPLICATIONS THEREOF |
| WO2012145069A2 (en) * | 2011-02-24 | 2012-10-26 | The University Of Toledo | Materials and methods useful to induce cell death via methuosis |
| CN102250065B (zh) * | 2011-05-20 | 2015-05-13 | 浙江海正药业股份有限公司 | 取代的三嗪苯脲衍生物及其用途 |
| CA3023854A1 (en) | 2016-05-12 | 2017-11-16 | Nanjing Shiqi Pharmaceutical Co. Ltd. | Novel 2,4,6-trisubstituted s-triazine compounds, preparation method therefor, and use thereof |
-
2017
- 2017-05-11 CA CA3023854A patent/CA3023854A1/en active Pending
- 2017-05-11 BR BR112018072869-1A patent/BR112018072869B1/pt active IP Right Grant
- 2017-05-11 DK DK17795572.1T patent/DK3456712T3/da active
- 2017-05-11 KR KR1020187035570A patent/KR102379959B1/ko active IP Right Grant
- 2017-05-11 CN CN201780028741.2A patent/CN109311825B/zh active Active
- 2017-05-11 ES ES17795572T patent/ES2913982T3/es active Active
- 2017-05-11 EP EP17795572.1A patent/EP3456712B1/en active Active
- 2017-05-11 WO PCT/CN2017/083914 patent/WO2017193954A1/zh unknown
- 2017-05-11 AU AU2017262920A patent/AU2017262920B2/en active Active
- 2017-05-11 RU RU2018141762A patent/RU2737085C2/ru active
- 2017-05-11 SG SG11201809760TA patent/SG11201809760TA/en unknown
- 2017-05-11 US US16/300,162 patent/US10611736B2/en active Active
- 2017-05-11 JP JP2019512032A patent/JP6987125B2/ja active Active
-
2020
- 2020-02-26 US US16/802,378 patent/US11390591B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190003765A (ko) | 2019-01-09 |
| KR102379959B1 (ko) | 2022-03-29 |
| JP2019515049A (ja) | 2019-06-06 |
| CN109311825A (zh) | 2019-02-05 |
| SG11201809760TA (en) | 2018-12-28 |
| EP3456712A1 (en) | 2019-03-20 |
| JP6987125B2 (ja) | 2021-12-22 |
| EP3456712B1 (en) | 2022-04-20 |
| EP3456712A4 (en) | 2019-12-04 |
| RU2737085C2 (ru) | 2020-11-24 |
| US10611736B2 (en) | 2020-04-07 |
| ES2913982T3 (es) | 2022-06-07 |
| RU2018141762A (ru) | 2020-06-15 |
| BR112018072869B1 (pt) | 2024-02-27 |
| US11390591B2 (en) | 2022-07-19 |
| CA3023854A1 (en) | 2017-11-16 |
| BR112018072869A2 (pt) | 2019-04-30 |
| AU2017262920A1 (en) | 2018-11-29 |
| RU2018141762A3 (da) | 2020-06-15 |
| CN109311825B (zh) | 2022-03-22 |
| AU2017262920B2 (en) | 2021-05-20 |
| US20190144399A1 (en) | 2019-05-16 |
| US20200190042A1 (en) | 2020-06-18 |
| WO2017193954A1 (zh) | 2017-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272089B1 (en) | Compounds, preparations and methods | |
| DK3676297T3 (da) | Forbindelser, sammensætninger og fremgangsmåder | |
| DK3411358T3 (da) | Substitueret piperidinforbindelse og anvendelse deraf. | |
| IL248546A0 (en) | A polysubstituted fluorine compound as a proton tyrosine kinase inhibitor | |
| DK3407888T3 (da) | Pyridopyrroloquinoxalinforbindelser, deres sammensætninger og anvendelser | |
| DK3330258T3 (da) | 1, 3, 5-triazinderivat og fremgangsmåde til anvendelse af samme | |
| DK3408326T3 (da) | Elastomerartikler, sammensætninger og fremgangsmåder til fremstilling deraf | |
| DK3207130T3 (da) | Sammensætninger af Adenosin Deaminase-2 (ADA2), varianter deraf og fremgangsmåder til anvendelse af samme | |
| DK3297637T3 (da) | Benzen-1,3,5-tricarboxamidderivater og anvendelser deraf | |
| DK3497081T3 (da) | Fremgangsmåde til fremstilling af 4-ammonium-2,2,6,6-tetraalkylpiperidinylsalte | |
| EP3466943A4 (en) | DIPHENYLAMINOPYRIMIDINE AND TRIAZINE COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
| PL3135668T3 (pl) | Nowy dipodstawiony związek 1,2,4-triazynowy | |
| DK3750893T3 (da) | Dioxazolinforbindelse, fremgangsmåde til fremstilling deraf og anvendelser deraf | |
| PT3552017T (pt) | Compostos úteis como inibidores de ripk1 | |
| PT3438103T (pt) | Composto de griseofulvina | |
| ZA201701132B (en) | Novel 2,5-substituted pyrimidines as pde inhibitors | |
| DK3662925T3 (da) | Sammensætning, der omfatter fsh, til behandling af infertilitet | |
| DK3719021T3 (da) | Inhibitorer af adapterassocieret kinase 1, sammensætninger omfattende disse og fremgangsmåder til anvendelse deraf | |
| DK3456712T3 (da) | Hidtil ukendte 2,4,6-trisubstitueret S-triazinforbindelse, fremgangsmåde til fremstilling deraf og anvendelse deraf | |
| SG11201803584RA (en) | 1,4-dicarbonyl-piperidyl derivatives | |
| IL258217A (en) | 2,3,4,5 tetrahydropyridin-6-amine derivatives | |
| DK3604303T3 (da) | Hidtil ukendt pyrrolopyridinderivat, fremgangsmåde til fremstilling heraf og anvendelse deraf | |
| SG11201705088VA (en) | 3,5-diaminopyrazole kinase inhibitors | |
| DK3181556T5 (da) | Mikromolekyleforbindelse, fremgangsmåde til syntese og anvendelse deraf | |
| IL254454A0 (en) | Chemical synthesis methods of bivalent compounds related to pyrrole and their preparations |